Conditions: Hepatic Impairment
Keywords: BAF312 Pharmacokinetics Hepatic impairment
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 40
Healthy volunteers: yes

Brief summary:
This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.

Detailed description:

Arms:
arm 1: Treatment with a single oral dose of 0.25 mg BAF312 arm 2: Treatment with a single oral dose of 0.25 mg BAF312 arm 3: Treatment with a single oral dose of 0.25 mg BAF312 arm 4: Treatment with a single oral dose of 0.25 mg BAF312

Interventions: intervention 1: BAF312
Intervention descriptions: intervention 1: Treatment with a single oral dose of 0.25 mg BAF312

Protocol document: